PSMA-1007
PSMA-1007 is a novel Glu-Ureido-based prostate-specific membrane antigen (PSMA) inhibitor designed for use in positron emission tomography (PET) imaging of prostate cancer. It belongs to the class of small-molecule PSMA inhibitors that specifically target PSMA, a transmembrane protein highly expressed in prostate cancer cells and the neovasculature of other solid tumors. PSMA-1007 is particularly notable for its favorable pharmacokinetic properties, including high tumor uptake and low urinary excretion, making it an excellent tool for prostate cancer diagnosis and staging.
Product Specifications
CAS Number
2226894-58-0
Purity
>98%
Smiles
C (F) (F) (F) C (=O) [O-].C (C1C=CC2C=CC=CC=2C=1) [C@@H] (C (=O) NCCCC[C@@H] (C (=O) O) NC (=O) N[C@H] (C (=O) O) CCC (=O) O) NC (C1C=CC (CNC (=O) [C@H] (CCC (=O) O) NC (=O) [C@H] (CCC (=O) O) NC (C2=CN=C ([N+] (C) (C) C) C=C2) =O) =CC=1) =O
Molecular Formula
C54H64F3N9O18
Molecular Weight
1184.1306848526
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
